<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1969">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04351516</url>
  </required_header>
  <id_info>
    <org_study_id>COVID65plus</org_study_id>
    <secondary_id>2020-001482-37</secondary_id>
    <nct_id>NCT04351516</nct_id>
  </id_info>
  <brief_title>Test and Treat COVID 65plus+</brief_title>
  <acronym>COVID65plus</acronym>
  <official_title>Randomized Controlled Trial of Hydroxychloroquine Versus Placebo in Early Ambulatory Diagnosis and Treatment of Elderly COVID19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients over equal or older than 65 yearswill be treated with a hydroxychloroquine versus&#xD;
      placebo reduced loading dose of 600mg on the first day followed with 400mg/day divided in&#xD;
      2x200mg for 6 more days resulting in a total duration of therapy of 7 days. Measurement of&#xD;
      Hydroxychloroquine-levels will be performed on day 7, . A follow-up by video or telephone&#xD;
      conference will be performed to observe drug intake and collect adverse events during&#xD;
      treatment phase on a daily base on working days and once during the weekend (i.e. 6 out of 7&#xD;
      days). After treatment phase follow-up by telephone calls will be done on day 10, 30, 60 (+/-&#xD;
      2 days).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No Patients enrolled&#xD;
  </why_stopped>
  <start_date type="Actual">April 21, 2020</start_date>
  <completion_date type="Anticipated">May 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>● Rate of hospitalization or death at day 7 after study inclusion</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>SARS-CoV 2</condition>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>hydroxychloroquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>dose of 600mg on the first day followed with 400mg/day divided in 2x200mg for 6 more days</description>
    <arm_group_label>hydroxychloroquine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo: Film Coated Tablette</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Age ≥ 65 years&#xD;
&#xD;
          -  Mild to moderate symptomatic respiratory tract Infection defined as not requiring&#xD;
             hospital admission: SpO2 &gt;94%, respiratory rate &lt;20, mental state alert, no signs of&#xD;
             septic shock&#xD;
&#xD;
          -  Proven SARS-Cov2 infection by throat swab (PCR)&#xD;
&#xD;
          -  Onset of symptoms within the last 3 days before randomization&#xD;
&#xD;
          -  Must be able to adhere to the study visit schedule and other protocol requirements in&#xD;
             the investigator's opinion. I.e. must be able to answer to questions concerning&#xD;
             symptoms and side effects and must be able to consent to the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hospitalization at study inclusion&#xD;
&#xD;
          -  Weight &lt;50 kg&#xD;
&#xD;
          -  Acute myocardial infarction&#xD;
&#xD;
          -  Severe heart failure, characterized as NYHA class 3 or 4&#xD;
&#xD;
          -  Use of concomitant medications that prolong the QT/QTc interval.&#xD;
&#xD;
          -  QTc &gt;450ms&#xD;
&#xD;
          -  Bilirubin ≥ 1,5 x UNL, (except for known M. Meulengracht)&#xD;
&#xD;
          -  AST/ALT ≥ 3 x ULN&#xD;
&#xD;
          -  Albumine ≤ 2.8 g/dl&#xD;
&#xD;
          -  Hemoglobin ≤ 9 g/dl&#xD;
&#xD;
          -  Leucocytes ≤ 2000/µl&#xD;
&#xD;
          -  Neutrophiles ≤ 1000/µl&#xD;
&#xD;
          -  Thrombocytes ≤ 100.000/µl&#xD;
&#xD;
          -  Troponin elevation&#xD;
&#xD;
          -  BNP &gt; 500 pg/ml&#xD;
&#xD;
          -  Creatine kinase &gt; 5 x ULN&#xD;
&#xD;
          -  Creatinine &gt;1,5 mg/dl&#xD;
&#xD;
          -  Uncorrected hypopotassemia or hypomagnesemia&#xD;
&#xD;
          -  History of hypoglycemic events&#xD;
&#xD;
          -  History of or present cardial arrhythmia (except atrial fibrillation or paroxysmal&#xD;
             supraventricular tachycardia)&#xD;
&#xD;
          -  Bradycardia &lt; 60 beats/min&#xD;
&#xD;
          -  History of Retinopathy or Maculopathy&#xD;
&#xD;
          -  Psoriasis&#xD;
&#xD;
          -  Myasthenia gravis&#xD;
&#xD;
          -  Epilepsy&#xD;
&#xD;
          -  Immunodeficiency syndromes or need for highly immunosuppressive medication&#xD;
&#xD;
          -  Pre-existing medication with hydroxychloroquine&#xD;
&#xD;
          -  Known G6PD deficiency.&#xD;
&#xD;
          -  Participation in another interventional study&#xD;
&#xD;
          -  Known hypersensibility to hydroxychloroquine and its derivates&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Uniklinikum Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 15, 2020</study_first_submitted>
  <study_first_submitted_qc>April 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2020</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

